Elevated soluble CD30 correlates with development of bronchiolitis obliterans syndrome following lung transplantation

Ryan C. Fields, Ankit Bharat, Nancy Steward, Aviva Aloush, Brian F. Meyers, Elbert P. Trulock, William C. Chapman, G. Alexander Patterson, Thalachallour Mohanakumar*

*Corresponding author for this work

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND. The long-term function of lung transplants is limited by chronic rejection (bronchiolitis obliterans syndrome, BOS). Due to lack of specific markers, BOS is diagnosed clinically. Because there is strong evidence that alloimmunity plays a significant role in the pathogenesis of BOS, we investigated whether soluble CD30 (sCD30), a T-cell activation marker, would correlate with BOS. METHODS. Sera collected serially from BOS+ (n=20) and matched BOS- (n=20) lung transplant (LT) patients were analyzed for sCD30 by enzyme-linked immunosorbent assay. Pretransplant sera and sera from normal donors were also analyzed. RESULTS. PreLT levels were comparable to normal subjects. However, posttransplant there was a significant elevation in sCD30 levels during BOS development in all BOS+ patients, compared to BOS- (mean 139.8±10.7 vs. 14.8±2.7 U/ml, P<0.001). sCD30 levels declined in the BOS+ patients but were still elevated compared to BOS- (48.52±5.04 vs. 7.19±2.9, P<0.0001). CONCLUSIONS. We conclude that sCD30 may represent a novel marker to monitor the development of BOS.

Original languageEnglish (US)
Pages (from-to)1596-1601
Number of pages6
JournalTransplantation
Volume82
Issue number12
DOIs
StatePublished - Dec 1 2006

Fingerprint

Bronchiolitis Obliterans
Lung Transplantation
Serum
Transplants
Lung

Keywords

  • Bronchiolitis obliterans
  • Chronic rejection
  • Lung transplantation
  • Markers of rejection
  • sCD30

ASJC Scopus subject areas

  • Transplantation

Cite this

Fields, Ryan C. ; Bharat, Ankit ; Steward, Nancy ; Aloush, Aviva ; Meyers, Brian F. ; Trulock, Elbert P. ; Chapman, William C. ; Patterson, G. Alexander ; Mohanakumar, Thalachallour. / Elevated soluble CD30 correlates with development of bronchiolitis obliterans syndrome following lung transplantation. In: Transplantation. 2006 ; Vol. 82, No. 12. pp. 1596-1601.
@article{d892316e14354d508d459082a0b1e5a6,
title = "Elevated soluble CD30 correlates with development of bronchiolitis obliterans syndrome following lung transplantation",
abstract = "BACKGROUND. The long-term function of lung transplants is limited by chronic rejection (bronchiolitis obliterans syndrome, BOS). Due to lack of specific markers, BOS is diagnosed clinically. Because there is strong evidence that alloimmunity plays a significant role in the pathogenesis of BOS, we investigated whether soluble CD30 (sCD30), a T-cell activation marker, would correlate with BOS. METHODS. Sera collected serially from BOS+ (n=20) and matched BOS- (n=20) lung transplant (LT) patients were analyzed for sCD30 by enzyme-linked immunosorbent assay. Pretransplant sera and sera from normal donors were also analyzed. RESULTS. PreLT levels were comparable to normal subjects. However, posttransplant there was a significant elevation in sCD30 levels during BOS development in all BOS+ patients, compared to BOS- (mean 139.8±10.7 vs. 14.8±2.7 U/ml, P<0.001). sCD30 levels declined in the BOS+ patients but were still elevated compared to BOS- (48.52±5.04 vs. 7.19±2.9, P<0.0001). CONCLUSIONS. We conclude that sCD30 may represent a novel marker to monitor the development of BOS.",
keywords = "Bronchiolitis obliterans, Chronic rejection, Lung transplantation, Markers of rejection, sCD30",
author = "Fields, {Ryan C.} and Ankit Bharat and Nancy Steward and Aviva Aloush and Meyers, {Brian F.} and Trulock, {Elbert P.} and Chapman, {William C.} and Patterson, {G. Alexander} and Thalachallour Mohanakumar",
year = "2006",
month = "12",
day = "1",
doi = "10.1097/01.tp.0000241076.46033.4c",
language = "English (US)",
volume = "82",
pages = "1596--1601",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

Fields, RC, Bharat, A, Steward, N, Aloush, A, Meyers, BF, Trulock, EP, Chapman, WC, Patterson, GA & Mohanakumar, T 2006, 'Elevated soluble CD30 correlates with development of bronchiolitis obliterans syndrome following lung transplantation', Transplantation, vol. 82, no. 12, pp. 1596-1601. https://doi.org/10.1097/01.tp.0000241076.46033.4c

Elevated soluble CD30 correlates with development of bronchiolitis obliterans syndrome following lung transplantation. / Fields, Ryan C.; Bharat, Ankit; Steward, Nancy; Aloush, Aviva; Meyers, Brian F.; Trulock, Elbert P.; Chapman, William C.; Patterson, G. Alexander; Mohanakumar, Thalachallour.

In: Transplantation, Vol. 82, No. 12, 01.12.2006, p. 1596-1601.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Elevated soluble CD30 correlates with development of bronchiolitis obliterans syndrome following lung transplantation

AU - Fields, Ryan C.

AU - Bharat, Ankit

AU - Steward, Nancy

AU - Aloush, Aviva

AU - Meyers, Brian F.

AU - Trulock, Elbert P.

AU - Chapman, William C.

AU - Patterson, G. Alexander

AU - Mohanakumar, Thalachallour

PY - 2006/12/1

Y1 - 2006/12/1

N2 - BACKGROUND. The long-term function of lung transplants is limited by chronic rejection (bronchiolitis obliterans syndrome, BOS). Due to lack of specific markers, BOS is diagnosed clinically. Because there is strong evidence that alloimmunity plays a significant role in the pathogenesis of BOS, we investigated whether soluble CD30 (sCD30), a T-cell activation marker, would correlate with BOS. METHODS. Sera collected serially from BOS+ (n=20) and matched BOS- (n=20) lung transplant (LT) patients were analyzed for sCD30 by enzyme-linked immunosorbent assay. Pretransplant sera and sera from normal donors were also analyzed. RESULTS. PreLT levels were comparable to normal subjects. However, posttransplant there was a significant elevation in sCD30 levels during BOS development in all BOS+ patients, compared to BOS- (mean 139.8±10.7 vs. 14.8±2.7 U/ml, P<0.001). sCD30 levels declined in the BOS+ patients but were still elevated compared to BOS- (48.52±5.04 vs. 7.19±2.9, P<0.0001). CONCLUSIONS. We conclude that sCD30 may represent a novel marker to monitor the development of BOS.

AB - BACKGROUND. The long-term function of lung transplants is limited by chronic rejection (bronchiolitis obliterans syndrome, BOS). Due to lack of specific markers, BOS is diagnosed clinically. Because there is strong evidence that alloimmunity plays a significant role in the pathogenesis of BOS, we investigated whether soluble CD30 (sCD30), a T-cell activation marker, would correlate with BOS. METHODS. Sera collected serially from BOS+ (n=20) and matched BOS- (n=20) lung transplant (LT) patients were analyzed for sCD30 by enzyme-linked immunosorbent assay. Pretransplant sera and sera from normal donors were also analyzed. RESULTS. PreLT levels were comparable to normal subjects. However, posttransplant there was a significant elevation in sCD30 levels during BOS development in all BOS+ patients, compared to BOS- (mean 139.8±10.7 vs. 14.8±2.7 U/ml, P<0.001). sCD30 levels declined in the BOS+ patients but were still elevated compared to BOS- (48.52±5.04 vs. 7.19±2.9, P<0.0001). CONCLUSIONS. We conclude that sCD30 may represent a novel marker to monitor the development of BOS.

KW - Bronchiolitis obliterans

KW - Chronic rejection

KW - Lung transplantation

KW - Markers of rejection

KW - sCD30

UR - http://www.scopus.com/inward/record.url?scp=33845935692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845935692&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000241076.46033.4c

DO - 10.1097/01.tp.0000241076.46033.4c

M3 - Article

VL - 82

SP - 1596

EP - 1601

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -